{"id":61867,"date":"2026-03-30T18:44:17","date_gmt":"2026-03-30T10:44:17","guid":{"rendered":"https:\/\/flcube.com\/?p=61867"},"modified":"2026-03-30T18:44:18","modified_gmt":"2026-03-30T10:44:18","slug":"clover-biopharmaceuticals-completes-enrollment-in-phase-ii-trial-of-trimer-tag-respiratory-combination-vaccines-for-older-adults","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61867","title":{"rendered":"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults"},"content":{"rendered":"\n<p><strong>Clover Biopharmaceuticals Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2197:HKG\">HKG: 2197<\/a>) announced the <strong>completion of subject enrollment<\/strong> in a <strong>Phase II clinical trial<\/strong> in Australia for its novel <strong>respiratory combination vaccine candidates<\/strong>, <strong>SCB 1022<\/strong> and <strong>SCB 1033<\/strong>. Both candidates leverage Clover\u2019s proprietary <strong>Trimer-Tag\u00ae protein trimerization platform<\/strong> to present <strong>pre-fusion F (Pre-F) trimeric antigens<\/strong>\u2014a conformation proven to elicit potent neutralizing antibodies against respiratory viruses. The study targets <strong>older adults aged 60\u201385<\/strong>, a high-risk population for severe lower respiratory tract infections, with <strong>topline results expected in Q3 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design\">Clinical Trial Design<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase<\/strong><\/td><td>II<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Randomized, observer-blind, multi-center<\/td><\/tr><tr><td><strong>Location<\/strong><\/td><td>Australia<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>420 older adults (60\u201385 years)<\/td><\/tr><tr><td><strong>Arms<\/strong><\/td><td>SCB 1022 \/ SCB 1033 \/ Placebo<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>Safety, reactogenicity, immunogenicity<\/td><\/tr><tr><td><strong>Expected Readout<\/strong><\/td><td>Q3 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The trial represents one of the first mid-stage studies evaluating <strong>multi-virus respiratory vaccines<\/strong> in an elderly cohort outside of influenza or RSV monovalent programs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-vaccine-candidates-overview\">Vaccine Candidates Overview<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scb-1022\"><strong>SCB 1022<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targets<\/strong>: <strong>Respiratory syncytial virus (RSV)<\/strong> + <strong>Human metapneumovirus (hMPV)<\/strong><\/li>\n\n\n\n<li><strong>Antigen Format<\/strong>: Pre-F trimeric subunits fused to Trimer-Tag\u00ae for stability and immunogenicity<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scb-1033\"><strong>SCB 1033<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targets<\/strong>: <strong>RSV + hMPV + Parainfluenza virus type 3 (PIV3)<\/strong><\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: First publicly disclosed <strong>trivalent non-influenza respiratory vaccine candidate<\/strong> using native-like Pre-F trimers<\/li>\n<\/ul>\n\n\n\n<p>All antigens are produced via <strong>mammalian cell expression<\/strong>, ensuring proper glycosylation and conformational fidelity\u2014a key advantage over nanoparticle or mRNA platforms for fusion protein vaccines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-platform-advantage-trimer-tag-technology\">Platform Advantage: Trimer-Tag\u00ae Technology<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Fuses target antigens to a <strong>collagen-derived trimerization domain<\/strong>, forcing stable <strong>homotrimer formation<\/strong><\/li>\n\n\n\n<li><strong>Proven Track Record<\/strong>: Underpinned Clover\u2019s <strong>RSVPreF3 OA vaccine<\/strong>, which demonstrated <strong>>80% efficacy<\/strong> in Phase III elderly trials<\/li>\n\n\n\n<li><strong>Manufacturing Scalability<\/strong>: Uses standard bioreactor processes compatible with global CMO infrastructure<\/li>\n<\/ul>\n\n\n\n<p>By presenting antigens in their <strong>native pre-fusion conformation<\/strong>, Trimer-Tag\u00ae vaccines mimic viral surface structures more accurately, driving higher-quality immune responses.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need<\/strong>: No approved vaccines exist for <strong>hMPV or PIV3<\/strong>, despite causing <strong>~20% of pediatric and elderly hospitalizations<\/strong> for bronchiolitis and pneumonia<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Combined annual burden of RSV, hMPV, and PIV3 exceeds <strong>50 million cases globally<\/strong> in at-risk populations<\/li>\n\n\n\n<li><strong>Commercial Pathway<\/strong>: Success could position Clover as a leader in <strong>next-generation respiratory vaccines<\/strong>, complementing its existing RSV program and enabling combination strategies with seasonal flu shots<\/li>\n<\/ul>\n\n\n\n<p>Positive data may trigger <strong>partnership interest from global vaccine majors<\/strong> seeking to expand beyond influenza and SARS-CoV-2.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, immunogenicity outcomes, and strategic opportunities. Actual results may differ due to trial variability, regulatory feedback, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033000010_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026033000010_c.\"><\/object><a id=\"wp-block-file--media-33b799c9-9c12-430a-8cdd-aba46e5578ff\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033000010_c.pdf\">2026033000010_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033000010_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-33b799c9-9c12-430a-8cdd-aba46e5578ff\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,651,1123,12],"class_list":["post-61867","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-clover-biopharmaceuticals","tag-hkg-2197","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II clinical trial in Australia for its novel respiratory combination vaccine candidates, SCB 1022 and SCB 1033. Both candidates leverage Clover\u2019s proprietary Trimer-Tag\u00ae protein trimerization platform to present pre-fusion F (Pre-F) trimeric antigens\u2014a conformation proven to elicit potent neutralizing antibodies against respiratory viruses. The study targets older adults aged 60\u201385, a high-risk population for severe lower respiratory tract infections, with topline results expected in Q3 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61867\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults\" \/>\n<meta property=\"og:description\" content=\"Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II clinical trial in Australia for its novel respiratory combination vaccine candidates, SCB 1022 and SCB 1033. Both candidates leverage Clover\u2019s proprietary Trimer-Tag\u00ae protein trimerization platform to present pre-fusion F (Pre-F) trimeric antigens\u2014a conformation proven to elicit potent neutralizing antibodies against respiratory viruses. The study targets older adults aged 60\u201385, a high-risk population for severe lower respiratory tract infections, with topline results expected in Q3 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61867\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-30T10:44:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T10:44:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61867#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61867\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults\",\"datePublished\":\"2026-03-30T10:44:17+00:00\",\"dateModified\":\"2026-03-30T10:44:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61867\"},\"wordCount\":401,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Clover Biopharmaceuticals\",\"HKG: 2197\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61867#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61867\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61867\",\"name\":\"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-30T10:44:17+00:00\",\"dateModified\":\"2026-03-30T10:44:18+00:00\",\"description\":\"Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II clinical trial in Australia for its novel respiratory combination vaccine candidates, SCB 1022 and SCB 1033. Both candidates leverage Clover\u2019s proprietary Trimer-Tag\u00ae protein trimerization platform to present pre-fusion F (Pre-F) trimeric antigens\u2014a conformation proven to elicit potent neutralizing antibodies against respiratory viruses. The study targets older adults aged 60\u201385, a high-risk population for severe lower respiratory tract infections, with topline results expected in Q3 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61867#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61867\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61867#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults - Insight, China&#039;s Pharmaceutical Industry","description":"Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II clinical trial in Australia for its novel respiratory combination vaccine candidates, SCB 1022 and SCB 1033. Both candidates leverage Clover\u2019s proprietary Trimer-Tag\u00ae protein trimerization platform to present pre-fusion F (Pre-F) trimeric antigens\u2014a conformation proven to elicit potent neutralizing antibodies against respiratory viruses. The study targets older adults aged 60\u201385, a high-risk population for severe lower respiratory tract infections, with topline results expected in Q3 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61867","og_locale":"en_US","og_type":"article","og_title":"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults","og_description":"Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II clinical trial in Australia for its novel respiratory combination vaccine candidates, SCB 1022 and SCB 1033. Both candidates leverage Clover\u2019s proprietary Trimer-Tag\u00ae protein trimerization platform to present pre-fusion F (Pre-F) trimeric antigens\u2014a conformation proven to elicit potent neutralizing antibodies against respiratory viruses. The study targets older adults aged 60\u201385, a high-risk population for severe lower respiratory tract infections, with topline results expected in Q3 2026.","og_url":"https:\/\/flcube.com\/?p=61867","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-30T10:44:17+00:00","article_modified_time":"2026-03-30T10:44:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61867#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61867"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults","datePublished":"2026-03-30T10:44:17+00:00","dateModified":"2026-03-30T10:44:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61867"},"wordCount":401,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Clover Biopharmaceuticals","HKG: 2197","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61867#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61867","url":"https:\/\/flcube.com\/?p=61867","name":"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-30T10:44:17+00:00","dateModified":"2026-03-30T10:44:18+00:00","description":"Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II clinical trial in Australia for its novel respiratory combination vaccine candidates, SCB 1022 and SCB 1033. Both candidates leverage Clover\u2019s proprietary Trimer-Tag\u00ae protein trimerization platform to present pre-fusion F (Pre-F) trimeric antigens\u2014a conformation proven to elicit potent neutralizing antibodies against respiratory viruses. The study targets older adults aged 60\u201385, a high-risk population for severe lower respiratory tract infections, with topline results expected in Q3 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61867#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61867"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61867#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61867"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61867\/revisions"}],"predecessor-version":[{"id":61869,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61867\/revisions\/61869"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}